ClinicalTrials.gg

Program

pralurbactam

Also written as “Meropenem and Pralurbactam”, “FL058” and “Meropenem- FL058”.

Its studies are mostly in Pneumonia, Bacterial · Sepsis · Intraabdominal Infections · Pyelonephritis, led by Qilu Pharmaceutical.

Furthest: phase 3, since Sep 26, 20247 company-led studies, 3 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Qilu Pharmaceutical73 open or runningphase 3since Sep 26, 2024Sep 8, 2021Dec 2026phase 3 · NCT07089186

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 8, 2021First studies: 3 phase 1 studies in HealthyFirst studyNCT05058118, NCT05058105, NCT05055687
  2. Sep 18, 2021Phase 2 study in Complicated Urinary Tract InfectionNCT05060419 · 150 enrolled
  3. Sep 26, 2024Phase 3 study in Intraabdominal InfectionsNCT06633718 · 786 planned · China
  4. Jun 25, 2025Phase 3 study in SepsisNCT07089186 · 80 planned · China
  5. Dec 26, 2025Phase 3 study in Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial PneumoniaNCT07327619 · 420 planned · China

Ahead

  1. Dec 2026Primary completion: phase 3 study in SepsisNCT07089186
  2. May 30, 2027Primary completion: phase 3 study in Intraabdominal InfectionsNCT06633718
  3. Jun 2028Primary completion: phase 3 study in Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial PneumoniaNCT07327619

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07327619Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia · China3RecruitingJun 2028420
NCT07089186Sepsis · China3RecruitingDec 202680
NCT06633718Intraabdominal Infections · China3Not yet recruitingMay 30, 2027786
NCT05060419Complicated Urinary Tract Infection2UNKNOWNApr 29, 2022150
NCT05058118Healthy · China1CompletedJun 3, 202054
NCT05058105Healthy · China1CompletedFeb 24, 202140
NCT05055687Healthy · China1CompletedJul 27, 202020

How it is read

Names in the registry

  • “Meropenem and Pralurbactam”, 3 entries
  • “FL058”, 3 entries
  • “Meropenem- FL058”, 1 entry
  • “FL058 500mg and Meropenem 1000mg( IV 120min)”, 1 entry
  • “FL058 1000mg( IV 120min)”, 1 entry

Codes read as this program: FL058.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
pralurbactam (Qilu Pharmaceutical): development program | ClinicalTrials.gg